celecoxib has been researched along with Cancer of Larynx in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 7.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 3.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
| "Despite 3 years of treatment, the papillomatosis proved difficult to control, requiring a procedure approximately every 3 months." | 1.51 | Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. ( Bentley, PL; Coulter, MJ; Nelson, BL, 2019) |
| "Celecoxib can inhibit proliferation and induce apoptosis in a dose- and time-dependent manner, repress telomerase activity, decrease hTERT mRNA and Bcl-2 protein expression and increase Bax protein expression, PGE2 had no effect on telomerase." | 1.40 | Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis. ( Chen, XM; Fan, XL; Feng, HW; Jia, T; Xu, AT; Zhang, H; Zhang, HL; Zhao, YQ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klatka, J | 1 |
| Grywalska, E | 1 |
| Hymos, A | 1 |
| Guz, M | 1 |
| Polberg, K | 1 |
| Roliński, J | 1 |
| Stepulak, A | 1 |
| Bentley, PL | 1 |
| Coulter, MJ | 1 |
| Nelson, BL | 1 |
| Zhao, YQ | 1 |
| Feng, HW | 1 |
| Jia, T | 1 |
| Chen, XM | 1 |
| Zhang, H | 1 |
| Xu, AT | 1 |
| Zhang, HL | 1 |
| Fan, XL | 1 |
| Limsukon, A | 1 |
| Susanto, I | 1 |
| Soo Hoo, GW | 1 |
| Dubinett, SM | 1 |
| Batra, RK | 1 |
| Chen, Z | 1 |
| Zhang, X | 1 |
| Li, M | 1 |
| Wang, Z | 1 |
| Wieand, HS | 1 |
| Grandis, JR | 1 |
| Shin, DM | 1 |
| Ding, J | 1 |
| Chang, Q | 1 |
| Gong, S | 1 |
| Wu, R | 1 |
| Abramson, AL | 1 |
| Shikowitz, MJ | 1 |
| Dannenberg, AJ | 1 |
| Steinberg, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis[NCT00571701] | Phase 2 | 50 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean plasma levels of celecoxib over months 3-12 in first treatment period correlated with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | pg. celecoxib/ml. plasma (Mean) |
|---|---|
| Responders | 151.3 |
| Non-responders | 543.41 |
Percent of patients of each gender with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to12 months
| Intervention | percent responders (Number) |
|---|---|
| Celecoxib First - Males | 12.50 |
| Placebo First- Males | 40.00 |
| Celecoxib First- Females | 12.50 |
| Placebo First- Females | 0.00 |
Percent of patients with HPV 6 versus patients with HPV 11 with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent of responders (Number) |
|---|---|
| Celecoxib First - HPV 6 | 9.09 |
| Placebo First- HPV 6 | 42.86 |
| Celecoxib First- HPV 11 | 25.00 |
| Placebo First- HPV 11 | 0.00 |
Percent of juvenile versus adult onset patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percentage of responders (Number) |
|---|---|
| Celecoxib First- Juvenile Onset | 12.50 |
| Placebo First- Juvenile-onsent | 7.69 |
| Celecoxib First - Adult Onset | 12.50 |
| Placebo First- Adult-onset | 33.33 |
Percent of patients who responded to celecoxib with increase in papilloma growth rate of no greater than 0.01 at end of second treatment period compared to growth rate at end of first treatment period. (NCT00571701)
Timeframe: End of first treatment period (month 12) to end of second treatment period (month 24)
| Intervention | percent of patients (Number) |
|---|---|
| Celecoxib Responders-maintained | 100 |
Change in mean growth rates during the last 3 months of the first treatment period compared to the mean values at baseline. Endoscopy and removal of all tumor was done every 3 months. Growth rate is calculated as the scored amount of papilloma recurrence in a 3 month period divided by the exact number of days since last endoscopy and removal of all tumor. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent change in mean growth rate (Mean) |
|---|---|
| Celecoxib First, Then Placebo | -5.4 |
| Placebo First, Then Celecoxib | -15.2 |
Percent of patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent responders (Number) |
|---|---|
| Celecoxib First (12 Months), Then Placebo (12 Months) | 12.5 |
| Placebo First (12 Months), Then Celecoxib (12 Months) | 28.6 |
7 other studies available for celecoxib and Cancer of Larynx
| Article | Year |
|---|---|
Cyclooxygenase-2 Inhibition Enhances Proliferation of NKT Cells Derived from Patients with Laryngeal Cancer.
Topics: Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Human | 2017 |
Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Human Papillomavirus Recombinant Vaccine Quadriv | 2019 |
Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis.
Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Proliferation; Cyclooxygenas | 2014 |
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hyd | 2009 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase | 2004 |
Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-R | 2005 |
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Topics: Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cycl | 2005 |